Bamlanivimab (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bamlanivimab" in German language version.

refsWebsite

Global rank German rank

4fda.gov

447^th place

751^st place

4europa.eu

68^th place

29^th place

3doi.org

2^nd place

3^rd place

1who.int

195^th place

255^th place

1pharmazeutische-zeitung.de

8,614^th place

583^rd place

1spiegel.de

66^th place

4^th place

1aerzteblatt.de

3,043^rd place

200^th place

1nih.gov

4^th place

7^th place

1oup.com

485^th place

715^th place

aerzteblatt.de (Global: 3,043^rd place; German: 200^th place)

COVID-19: Erstes Antikörperpräparat erzielt Schutzwirkung bei leichteren Erkrankungen, www.aerzteblatt.de, 17. September 2020.

doi.org (Global: 2^nd place; German: 3^rd place)

P. Chen et al.: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. The New England Journal of Medicines, 28. Oktober 2020. doi:10.1056/NEJMoa2029849
Arturo Casadevall, Nigel Paneth: Monoclonal Antibody Therapies for Infectious Diseases. In: Convalescent Plasma and Other Antibody Therapies for Infectious Diseases. Band 443. Springer Nature Switzerland, 2024, ISBN 978-3-03187166-5, S. 3–13, doi:10.1007/82_2024_265.
Michael Dougan, Masoud Azizad, Bharat Mocherla, Robert L Gottlieb, Peter Chen, Corey Hebert, Russell Perry, Joseph Boscia, Barry Heller, Jason Morris, Chad Crystal, Awawu Igbinadolor, Gregory Huhn, Jose Cardona, Imad Shawa, Princy Kumar, Andra Blomkalns, Andrew C Adams, Jacob Van Naarden, Kenneth L Custer, Jack Knorr, Gerard Oakley, Andrew E Schade, Timothy R Holzer, Philip J Ebert, Richard E Higgs, Janelle Sabo, Dipak R Patel, Matan C Dabora, Mark Williams, Paul Klekotka, Lei Shen, Daniel M Skovronsky, Ajay Nirula: A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. In: Clinical Infectious Diseases. Band 75, Nr. 1, 24. August 2022, S. e440–e449, doi:10.1093/cid/ciab912, PMC 9402688 (freier Volltext) – (oup.com).

europa.eu (Global: 68^th place; German: 29^th place)

ema.europa.eu

EMA starts rolling review of Eli Lilly antibodies bamlanivimab and etesemivab for COVID-19. In: www.ema.europa.eu. 11. März 2021, abgerufen am 11. März 2021 (englisch).
EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly, European Medicines Agency (europa.eu), 2. November 2021.
EMA reviewing data on monoclonal antibody use for COVID-19. In: www.ema.europa.eu. 4. Februar 2021, abgerufen am 16. Februar 2021 (englisch).
EMA issues advice on use of antibody combination (bamlanivimab / etesevimab). 5. März 2021, abgerufen am 5. März 2021.

fda.gov (Global: 447^th place; German: 751^st place)

Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19. U.S. Food and Drug Administration (FDA), 9. November 2020, abgerufen am 11. November 2020 (englisch).
Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab. 16. April 2020, abgerufen am 19. April 2021.
Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19. U.S. Food and Drug Administration (FDA), 9. Februar 2021, abgerufen am 16. Februar 2021 (englisch).
FDA Roundup: April 15, 2022, FDA, 15. April 2022.

nih.gov (Global: 4^th place; German: 7^th place)

ncbi.nlm.nih.gov

Michael Dougan, Masoud Azizad, Bharat Mocherla, Robert L Gottlieb, Peter Chen, Corey Hebert, Russell Perry, Joseph Boscia, Barry Heller, Jason Morris, Chad Crystal, Awawu Igbinadolor, Gregory Huhn, Jose Cardona, Imad Shawa, Princy Kumar, Andra Blomkalns, Andrew C Adams, Jacob Van Naarden, Kenneth L Custer, Jack Knorr, Gerard Oakley, Andrew E Schade, Timothy R Holzer, Philip J Ebert, Richard E Higgs, Janelle Sabo, Dipak R Patel, Matan C Dabora, Mark Williams, Paul Klekotka, Lei Shen, Daniel M Skovronsky, Ajay Nirula: A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. In: Clinical Infectious Diseases. Band 75, Nr. 1, 24. August 2022, S. e440–e449, doi:10.1093/cid/ciab912, PMC 9402688 (freier Volltext) – (oup.com).

oup.com (Global: 485^th place; German: 715^th place)

academic.oup.com

Michael Dougan, Masoud Azizad, Bharat Mocherla, Robert L Gottlieb, Peter Chen, Corey Hebert, Russell Perry, Joseph Boscia, Barry Heller, Jason Morris, Chad Crystal, Awawu Igbinadolor, Gregory Huhn, Jose Cardona, Imad Shawa, Princy Kumar, Andra Blomkalns, Andrew C Adams, Jacob Van Naarden, Kenneth L Custer, Jack Knorr, Gerard Oakley, Andrew E Schade, Timothy R Holzer, Philip J Ebert, Richard E Higgs, Janelle Sabo, Dipak R Patel, Matan C Dabora, Mark Williams, Paul Klekotka, Lei Shen, Daniel M Skovronsky, Ajay Nirula: A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. In: Clinical Infectious Diseases. Band 75, Nr. 1, 24. August 2022, S. e440–e449, doi:10.1093/cid/ciab912, PMC 9402688 (freier Volltext) – (oup.com).

pharmazeutische-zeitung.de (Global: 8,614^th place; German: 583^rd place)

A. Rößler: USA erteilen Notfallgenehmigung bei Covid-19, www.pharmazeutische-zeitung.de, 10. November 2020.

spiegel.de (Global: 66^th place; German: 4^th place)

Bamlanivimab: US-Behörde entzieht Antikörpermedikament Notfallzulassung. In: Spiegel Online. 19. April 2021, abgerufen am 19. April 2021.

who.int (Global: 195^th place; German: 255^th place)

Proposed INN: List 124 – COVID-19 (special edition). In: WHO Drug Information. Band 34, Nr. 3, 2020 (englisch, who.int [PDF]).

Bamlanivimab (German Wikipedia)

aerzteblatt.de (Global: 3,043rd place; German: 200th place)

doi.org (Global: 2nd place; German: 3rd place)

europa.eu (Global: 68th place; German: 29th place)

ema.europa.eu

fda.gov (Global: 447th place; German: 751st place)

nih.gov (Global: 4th place; German: 7th place)